About Biopticon
Biopticon is a Healthcare company based in Princeton (United States) founded in 2003. It operates as a device and software imaging of subcutaneous tumors in animals. It operates in the Healthcare and Technology sectors. Biopticon offers products and services including TumorImager 2 and TumorManager. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Imaging Systems. Its legal entity is Biopticon Corporation. Its competitors include NavVis, Impedimed, Rigaku, Speclipse and Anvajo and 4 more; 8 of its 9 listed competitors have raised funding.
Company details
Biopticon makes a hand-held imaging device that uses laser, photonics and image processing technologies to analyze subcutaneous tumors. The companys devices, TumorImager and TumorImager2, rapidly scan subcutaneous tumors (1 sec) without requiring the animal to be under anesthesia, providing highly sensitive, reproducible measurement of drug response. The instruments are meant for use on animals, especially for the study of subcutaneous xenograft tumors in rodents. Biopticon also makes a software product, TumorManager, which is a fully integrated platform that allows scientists to manage every aspect of subcutaneous xenograft studies from protocol design, randomization, dosing, data capture, graphics and statistical analysis. Customers include pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies.
- Headquarters Princeton, United States
- SectorsHealthcareTechnology
- Website biopticon.com
- Social LinkedIn X Facebook
- Legal Name Biopticon Corporation
- InvestorsNJEDA
& 1 more
Products & Services of Biopticon
Biopticon offers a comprehensive portfolio of products and services, including TumorImager 2 and TumorManager.
Provides fast and accurate 3D measurements of subcutaneous tumors in small animals.
Manages preclinical oncology studies from design to reporting and analysis.
Funding Insights of Biopticon
- Total Rounds 1
- Investors Count 2
All 1 funding rounds of Biopticon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2009 | – | Seed | – | – |
2 investors in total: 2 institutional.
Investors in Biopticon
Biopticon has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include NJEDA and RCTC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Economic development services are provided by NJEDA in New Jersey. | – | njeda.com | Trenton, United States | |
- | – | rutgersbiz.com | - |
Investor details for Biopticon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Biopticon
2 dated milestones of Biopticon across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Biopticon is founded.
- Funding First funding round.
Competitors of Biopticon
Biopticon has 9 listed competitors in our database, 8 of them funded. They include NavVis, Impedimed, Rigaku, Speclipse and Anvajo, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| navvis.com | 2013 | Munich, Germany | $75.21M | 188 | Digital twin-powered indoor navigation solutions are developed for enterprises. | |
| impedimed.com | 1999 | Carlsbad, United States | $3.44M | 76 | Technologies for non-invasive fluid status assessment and monitoring are developed. | |
| rigaku.com | 1951 | Tokyo, Japan | – | 293 | XRD, XRF, SAXS, Raman, metrology, and crystallography solutions are provided. | |
| speclipse.com | 2015 | Seongnam-si, South Korea | $10.55M | – | Molecular spectroscopy systems for early skin cancer detection are provided. | |
| anvajo.com | 2016 | Dresden, Germany | $17.32M | 66 | Point-of-care solutions for laboratory diagnostics are provided by Anvajo. | |
| revopoint3d.com | 2014 | Los Angeles, United States | $16.04M | – | 3D cameras and scanners are provided for object capture. | |
| spectra-analysis.com | 2004 | Boston, United States | $9.25M | 6 | Infrared spectroscopic instruments are provided for molecular analysis. | |
| ahurascientific.com | 2002 | Wilmington, United States | $17M | – | Optical systems are developed for identifying solid and liquid chemicals. | |
| lineardiagnostics.com | 2011 | Birmingham, United Kingdom | $4.08M | 4 | Molecular diagnostic tests for sexually transmitted infections are developed. |
Detailed competitors of Biopticon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biopticon
The website of Biopticon (biopticon.com) receives about 4.1K visits a month.
- Monthly visits4.1K
▼ 46.3% vs previous month
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Biopticon (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Biopticon
Biopticon was founded in 2003 and raised its 1st funding round 6 years after it was founded.
Biopticon is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Biopticon makes a hand-held imaging device that uses laser, photonics and image processing technologies to analyze subcutaneous tumors. The companys devices, TumorImager and TumorImager2, rapidly scan subcutaneous tumors (1 sec) without requiring the animal to be under anesthesia, providing highly sensitive, reproducible measurement of drug response. The instruments are meant for use on animals, especially for the study of subcutaneous xenograft tumors in rodents. Biopticon also makes a software product, TumorManager, which is a fully integrated platform that allows scientists to manage every aspect of subcutaneous xenograft studies from protocol design, randomization, dosing, data capture, graphics and statistical analysis. Customers include pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies.
Biopticon's top competitors include NavVis, Revopoint 3D and Impedimed.
Biopticon offers TumorImager 2 and TumorManager.
Biopticon has 2 investors. Key investors include NJEDA, and RCTC.
Biopticon operates through Biopticon Corporation.